Pharmaceuticals & Therapeutics

InterAx's AI platform and Alveus's R&D expertise combine in a new partnership to develop a next-gen obesity drug with durable results and better tolerability.

A sudden collapse led to a rare cancer diagnosis for a NJ teen. His story of recovery highlights a therapy that targets tumors while sparing young minds.

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

A new synthetic bone graft powered by NanoLift™ technology promises to accelerate healing and improve outcomes for orthopedic and spinal surgery patients.

Reimbursements are falling and costs are rising, but top allergy practices are boosting revenue by 22%. A new report reveals their data-driven secrets.

Nordstrom and SkinSpirit are opening their fourth in-store clinic, blending medical aesthetics with luxury retail and making Botox as accessible as lipstick.

Eagle Pharmaceuticals divests its unique post-op nausea drug to France's LXO Group, signaling a strategic pivot to oncology and critical care.

The acquisition of NorCal Vein Specialists signals a shift to integrated care, reflecting a broader trend of consolidation in specialty medicine.

A new celebrity-backed eye drop promises freedom from reading glasses. We look at the science, the competition, and what it means for 128M Americans.

With its lead cancer therapy pelareorep showing promise, Oncolytics hires veteran execs to navigate the final hurdles of clinical trials and regulatory approval.

With major funding and a seasoned CEO, Caldera Therapeutics is advancing a first-in-class bispecific antibody into the clinic for inflammatory bowel disease.

As BD enters a new growth phase with interim leadership, the MedTech giant brings in Shawn Bevec, whose unique background bridges lab science and Wall Street.

In a major growth move, Franklin Street acquires hospitality leader Hodges Ward Elliott, creating a national CRE powerhouse with elite hotel brokerage expertise.

AstraZeneca's acquisition of Modella AI signals a major shift, embedding advanced AI directly into its cancer research to accelerate new treatments.

With new CEO Rebekah Gray at the helm, Gray Construction leverages its proven design-build model to tackle complex projects and power America's industrial resurgence.

The biopharma firm projects massive sales from its current drugs and bets big on a new Alzheimer's therapy, signaling a pivotal year of growth and innovation.

O Positiv's new menopause and metabolism products at Target signal a market shift. But how strong is the science behind these 'clinically studied' formulas?

A revolutionary bone graft that accelerates healing is now approved for more spinal surgeries, offering new hope to patients with chronic back pain.

For the third straight year, VIO Med Spa is the top franchise in its class. We explore the model driving its success in the booming wellness industry.

MedTech firm Lifeward is acquiring Oramed's oral insulin tech, despite a past trial failure, in a high-stakes deal that could redefine both companies.